Literature DB >> 22378916

Regional differences in incidence and patient characteristics of moyamoya disease: a systematic review.

Rachel Kleinloog1, Luca Regli, Gabriel J E Rinkel, Catharina J M Klijn.   

Abstract

BACKGROUND AND
PURPOSE: Moyamoya disease (MMD) is a rare cause of stroke, initially described in Japan. In other countries, incidences and presenting symptoms may differ from those in Japan. The literature on regional differences in incidence and patient characteristics of MMD was systematically reviewed.
METHODS: Medline, EMBASE and CINAHL were searched for population based studies on MMD published between January 1969 and January 2011. From studies that met predefined inclusion criteria, information was extracted on incidence and patient characteristics. Incidences with corresponding 95% CIs if possible were calculated and descriptive statistics for patient characteristics were used.
RESULTS: 8 studies were included: three from Japan, one each from Taiwan and China and three from the USA. Incidences per 100 000 patient years ranged in Japan from 0.35 to 0.94 (95% CI 0.69 to 1.19), in the USA from 0.05 (-0.04 to 0.12) in Iowa to 0.17 (-0.06 to 0.40) in Hawaii and were 0.41 (0.28 to 0.54) in Nanjing, China and 0.02 (0.003 to 0.04) in Taiwan. Female to male ratio ranged from 1.1 (0.9 to 1.5) in Nanjing to 2.8 (1.2 to 6.1) in Iowa. Proportions with intracerebral haemorrhage as the initial presentation were 56% in China, 52% in Taiwan, 29% in Hawaii, 21% in Japan and 10% in Iowa. Patients with childhood onset presented most often with ischaemia (>75%) in all regions.
CONCLUSIONS: MMD incidence was higher in Japan and China than in Taiwan and North America and presenting symptoms showed regional differences, which are thus far unexplained. Population based data on MMD in Europe are lacking.

Entities:  

Mesh:

Year:  2012        PMID: 22378916     DOI: 10.1136/jnnp-2011-301387

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  38 in total

1.  Cerebrovascular collaterals correlate with disease severity in adult North American patients with Moyamoya disease.

Authors:  M K Strother; M D Anderson; R J Singer; L Du; R D Moore; Y Shyr; T R Ladner; D Arteaga; M A Day; P F Clemmons; M J Donahue
Journal:  AJNR Am J Neuroradiol       Date:  2014-03-20       Impact factor: 3.825

2.  Missing relationship of moyamoya and persistent primitive artery in Europeans. Another distinctive feature or artifact?

Authors:  Holger Wenz; Ralf Wenz; Alex Förster; Johann Fontana; Hans Ulrich Kerl; Christoph Groden; Johann Scharf
Journal:  Surg Radiol Anat       Date:  2015-03-08       Impact factor: 1.246

Review 3.  Heritable and non-heritable uncommon causes of stroke.

Authors:  A Bersano; M Kraemer; A Burlina; M Mancuso; J Finsterer; S Sacco; C Salvarani; L Caputi; H Chabriat; S Lesnik Oberstein; A Federico; E Tournier Lasserve; D Hunt; M Dichgans; M Arnold; S Debette; H S Markus
Journal:  J Neurol       Date:  2020-04-21       Impact factor: 4.849

4.  Moyamoya disease and moyamoya syndrome in Ireland: patient demographics, mode of presentation and outcomes of EC-IC bypass surgery.

Authors:  Ronan J Doherty; John Caird; Darach Crimmins; Peter Kelly; Sean Murphy; Christopher McGuigan; Niall Tubridy; Mary D King; Bryan Lynch; David Webb; Desmond O'Neill; Dominick J H McCabe; Peter Boers; Mary O'Regan; Joan Moroney; David J Williams; Simon Cronin; Mohsen Javadpour
Journal:  Ir J Med Sci       Date:  2020-06-19       Impact factor: 1.568

5.  Circulating sortilin levels are associated with inflammation in patients with moyamoya disease.

Authors:  Wenxiu Han; Yi Qiao; Hailiang Zhang; Chunmei Geng; Xing Zhu; Dehua Liao; Yujin Guo; Mengqi Yang; Dan Chen; Pei Jiang
Journal:  Metab Brain Dis       Date:  2020-09-17       Impact factor: 3.584

6.  RNF213 rare variants in an ethnically diverse population with Moyamoya disease.

Authors:  Alana C Cecchi; Dongchuan Guo; Zhao Ren; Kelly Flynn; Regie Lyn P Santos-Cortez; Suzanne M Leal; Gao T Wang; Ellen S Regalado; Gary K Steinberg; Jay Shendure; Michael J Bamshad; James C Grotta; Deborah A Nickerson; Hariyadarshi Pannu; Dianna M Milewicz
Journal:  Stroke       Date:  2014-10-02       Impact factor: 7.914

Review 7.  Recent advances in moyamoya disease: pathophysiology and treatment.

Authors:  Annick Kronenburg; Kees P J Braun; Albert van der Zwan; Catharina J M Klijn
Journal:  Curr Neurol Neurosci Rep       Date:  2014-01       Impact factor: 5.081

8.  Patients with Moyamoya Vasculopathy Evaluated at a Single-Center in The Netherlands; Clinical Presentation and Outcome.

Authors:  Annick Kronenburg; Rachel Kleinloog; Albert van der Zwan; L Jaap Kappelle; Luca Regli; Kees P J Braun; Catharina J M Klijn
Journal:  J Clin Med       Date:  2021-04-27       Impact factor: 4.241

Review 9.  Moyamoya Disease and Spectrums of RNF213 Vasculopathy.

Authors:  Oh Young Bang; Jong-Won Chung; Dong Hee Kim; Hong-Hee Won; Je Young Yeon; Chang-Seok Ki; Hyung Jin Shin; Jong-Soo Kim; Seung Chyul Hong; Duk-Kyung Kim; Akio Koizumi
Journal:  Transl Stroke Res       Date:  2019-10-24       Impact factor: 6.829

Review 10.  Characteristics of Moyamoya Disease in the Older Population: Is It Possible to Define a Typical Presentation and Optimal Therapeutical Management?

Authors:  Ignazio G Vetrano; Anna Bersano; Isabella Canavero; Francesco Restelli; Gabriella Raccuia; Elisa F Ciceri; Giuseppe Faragò; Andrea Gioppo; Morgan Broggi; Marco Schiariti; Laura Gatti; Paolo Ferroli; Francesco Acerbi
Journal:  J Clin Med       Date:  2021-05-25       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.